Evidence map›Paper›PMID 30926963›Full record

ArticleGene therapy2019

A novel xenograft mouse model for testing approaches targeting human kappa light-chain diseases.

Xun Ma, Ping Zhou, Adin Kugelmass, Denis Toskic, Melissa Warner, Lisa Lee, Terry Fogaren, Amandeep Godara, Ming Wang, Yamin Li and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xun MaJohn Conant Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, USA.
Ping ZhouJohn Conant Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, USA.
Adin KugelmassJohn Conant Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, USA.
Denis ToskicJohn Conant Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, USA.
Melissa WarnerJohn Conant Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, USA.
Lisa LeeJohn Conant Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, USA.
Terry FogarenJohn Conant Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, USA.
Amandeep GodaraJohn Conant Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, USA.
Ming WangDepartment of Biomedical Engineering, Tufts University School of Medicine, Boston, MA, USA.
Yamin LiDepartment of Biomedical Engineering, Tufts University School of Medicine, Boston, MA, USA.
Liu YangDepartment of Biomedical Engineering, Tufts University School of Medicine, Boston, MA, USA.
Qiaobing XuDepartment of Biomedical Engineering, Tufts University School of Medicine, Boston, MA, USA.
Raymond L ComenzoJohn Conant Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, USA. rcomenzo@tuftsmedicalcenter.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with immunoglobulin (Ig) light-chain (LC) diseases such as LC light-chain amyloidosis die with organ failure and need new therapies. We sought a model to test anti-LC siRNA delivery to human plasma cells, requiring circulating LC, in vivo indicators of tumor presence, and capacity for multiple injections of delivery vehicle. The JJN-3 human myeloma reporter cell line expressing firefly luciferase (FFL) implanted intraperitoneally (IP) in the NOD scid γ (NSG) mouse has a 90% prompt tumor-take, rapid LC production, and in vivo indicators of tumor measurable on day 5 post-implant (κ LC, bioluminescent signal, and soluble B-cell maturation antigen [sBCMA]) with median day 5 serum levels of κ LC of 1482 ng/mL (range, 255-4831) and robust correlations with all in vivo indicators. In preliminary attempts to deliver siRNA against κ LC constant region mRNA, we identified the 306-O18B3 lipidoid nanoparticle (LNP) as promising, safe and efficient in vitro. In vivo in the JJN-3 NSG IP model, after daily IP 306-O18B3:siRNA injections on days 5-10, a reduction in κ LC was observed on day 8 between control and test groups that continued through day 12 at sacrifice. This model is potentially useful as a platform for refining anti-LC therapies.

Indexed as

Gene Transfer TechniquesAnimalsB-LymphocytesCell Line, TumorCells, CulturedFemaleHumansImmunoglobulin kappa-ChainsImmunoglobulin Light-chain AmyloidosisLuciferases, FireflyMiceMice, Inbred NODMice, SCIDNanoparticlesRNAi TherapeuticsXenograft Model Antitumor AssaysImmunoglobulin kappa-ChainsLuciferases, Firefly

Identifiers

PMID30926963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.